Can CAR-T and gene therapy cures really sustain biopharma? Not for all, analyst says – FiercePharma
FiercePharma |
Can CAR-T and gene therapy cures really sustain biopharma? Not for all, analyst says
FiercePharma Ever since 2012 when Novartis invested in personalized CAR-T cancer treatments being developed at the University of Pennsylvania, analysts have pondered a difficult question: How can pharma companies profit from curing patients? Now Novartis's CAR-T … |
